Biopsy clinical trials

Prospective Evaluation of AI R&D Tool for Patient Stratification - MoA Evaluation in Triple Negative Breast Cancer (PEAR-MET)

This study is testing a new tool for people with advanced triple-negative breast cancer. It uses a small sample of your tumour to see how it might react to different treatments. This helps researchers understand how to better choose treatments in the future, aiming to improve care for patients.